GlassScriptPhysician profile
Amber D Garner
NPI 1750821740
$8,414.40
in general payments reported to CMS, 2019-2025
44 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $3,924 · 2023: $1,318 · 2024: $1,560 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,258 · Education: $81.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,258.24 |
| Education | $81.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,647.69 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $746.44 | 2023-2025 | |
| Janssen Biotech, INC. | $430.26 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $350.59 | 2022-2025 | Enhertu, Imfinzi, Tagrisso |
| Novartis Pharmaceuticals Corporation | $326.94 | 2022-2025 | |
| Pfizer INC. | $260.72 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $243.91 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $229.68 | 2022-2025 | Enhertu, Datroway |
| Eisai INC. | $208.68 | 2022-2025 | |
| Seagen INC. | $194.94 | 2022-2023 | Tukysa, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $169.79 | 2022-2025 | Iclusig, Ninlaro, Fruzaqla |
| Sumitomo Pharma America, INC. | $164.41 | 2024-2025 | Orgovyx |
| Grt US Holding, INC. | $127.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $119.97 | 2023-2025 | Libtayo, Lynozyfic |
| Exelixis INC. | $110.98 | 2022-2025 | Cabometyx |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $109.51 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $104.78 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $77.54 | 2022-2024 | Opdivo |
| Incyte Corporation | $75.48 | 2023-2025 | Monjuvi, Jakafi |
| Rigel Pharmaceuticals, INC. | $71.34 | 2022-2024 | Rezlidhia, Tavalisse |
| Pharmacyclics LLC, An Abbvie Company | $53.39 | 2022-2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $50.42 | 2023-2024 | Brukinsa |
| G1 Therapeutics, INC. | $42.03 | 2023 | Cosela |
| Servier Pharmaceuticals LLC | $40.50 | 2024 | |
| Aveo Pharmaceuticals, INC. | $37.69 | 2023-2024 | Fotivda |
| Tempus Ai, INC | $34.42 | 2024-2025 | Xt Cdx |
| Genzyme Corporation | $33.95 | 2022-2024 | |
| Puma Biotechnology, INC. | $32.19 | 2024 | |
| Morphosys, US INC. | $31.62 | 2023 | Monjuvi |
| Tersera Therapeutics LLC | $29.79 | 2022 | |
| Pharmacosmos Therapeutics INC. | $28.91 | 2024 | Cosela, Monoferric |
| Pharmaessentia USA Corporation | $28.51 | 2023-2024 | Besremi |
| Beone Medicines USA, INC. | $21.76 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $20.92 | 2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.66 | 2023 | Gilotrif |
| Stimwave Technologies Incorporated | $18.68 | 2022 | |
| Stemline Therapeutics INC. | $17.99 | 2024 | Orserdu |
| Cti Biopharma Corp. | $15.79 | 2023 | Vonjo |
| Celgene Corporation | $15.13 | 2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $15.08 | 2023 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $14.76 | 2024 | Lorbrena, Mektovi, Braftovi |
| Mirati Therapeutics, INC. | $14.00 | 2023 | Krazati |
| Sobi, INC | $13.10 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.